Modified human immunodeficiency virus anti-fusogenic GP41 peptides comprising a maleimide-containing group
US7608271B2 · kind B2 · utility
5Cited by
11References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 24, 2004 |
| Grant date | Oct 27, 2009 |
| Priority date | — |
| Expiry date | Aug 10, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.